Published • loading... • Updated
Changing Fortunes: Is Biotech Giant CSL’s $10b Write-Down a Comeback Story?
The result beat expectations and lifted CSL’s outlook, even as the company flagged weaker sales at Vifor, Seqirus and Behring.
Summary by Sydney Morning Herald
3 Articles
3 Articles
Sydney Morning Herald+2 Reposted by 2 other sources
Changing fortunes: Is biotech giant CSL’s $10b write-down a comeback story?
Make no mistake: the home-grown biotechnology company, which for decades allowed Australia serious boasting rights, is still a long way from redemption.
·North Sydney, Australia
Read Full ArticleCoverage Details
Total News Sources3
Leaning Left3Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
